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mIDH1Lynch syndrome (LS) is an autosomal dominant tumour predisposition syndrome caused by a germlinemutation
in one of the DNA mismatch repair (MMR) genes.Patients with these mutations have an increased risk of brain
tumours, the vast majority of which are glioblastomas and medulloblastomas, and their occurrence has been
termed Turcot Syndrome. The case presented herein of amember of a Lynch syndrome familywith anMSH2mu-
tation expands the spectrum of brain tumours occurring in Lynch syndrome to include low grade astrocytomas,
and is the ﬁrst reported case of an IDH1 (R132H) mutated brain tumour occurring in a Lynch syndrome family.ment
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lynch syndrome (LS), previously known as hereditary nonpolyposis
colorectal carcinoma, is an autosomal dominant tumour predisposition
syndrome. It is caused by a germline mutation in one of the following
DNAMMR genes: MLH1 (MutL homologue 1), MSH2 (MutS homologue
2), MSH6 (MutS homologue 6), or PMS2 (Postmeiotic segregation 2).
Patients with a pathogenic DNA MMR gene mutation have a 10–50%
risk for developing colorectal carcinoma at an early age (mean 45–
50 years) and extracolonic malignancies can occur including endome-
trial, ovarian, hepatic, pancreatic and ureteric carcinomas and brain tu-
mours [1,2].Although the 1–3% lifetime risk of brain tumours is low
compared to other extracolonic tumours in LS families [1], this risk is
6 fold that of the general population and its occurrence has been termed
Turcot Syndrome. The brain tumours previously described in Lynch/
Turcot syndrome have mostly been high grade gliomas, predominantly
glioblastomas, and less commonly, medulloblastomas [1,3–6].A recent
European study described the risk of developing brain tumours being
highest (2.5%) in Lynch syndrome patients with MSH2 mutations,
contained the ﬁrst description of low grade astrocytoma in Lynch syn-
drome (1/47 gliomas was a pilocytic astrocytoma (WHO grade I), and
1/47 was a diffuse astrocytoma (WHO grade II)), and showed universal
negativity for mIDH1 immunoreactivity in Lynch syndrome associated
glioma [7].The present case adds to the sparse literature on low gradeof Anatomical Pathology,
ite E403, Toronto, Ontario,
en access article under theastrocytomas in Lynch syndrome and is the ﬁrst report of a Lynch syn-
drome associated IDH1 R132H mutated glioma.
The reader is reminded of previous work on expression of MLH1,
MSH2 and MSH6 immunohistochemistry in gliomas; namely that 43%
of astrocytoma have reduced expression of at least one MMR protein,
MSH2 negative staining is more frequent in lowgrade astrocytomas
(45%) than in high-grade astrocytomas (16%) [8], as well as the recent
interest inMMR deﬁciency as a predictor of temozolamide response, re-
currence and as a consequence of temozolamide treatment [9,10].
2. Case and methods
A 72 year old man had a previous diagnosis of colorectal carcinoma
and a family history of LS that included: colorectal carcinomas in his fa-
ther, brother, niece and several paternal aunts and uncles, breast carci-
noma and multiple sebaceous adenomas in his sister and ureteric
carcinoma and melanoma in his brother. Some family members met
criteria for the Muir–Torre variant of LS but our patient did not and no
previous family members had a brain tumour/Turcot syndrome. An
MSH2 mutation was found in the patient, his niece and sister
(560 T $_amp_$gt; C, exon 3). Our patient presented with rapidly pro-
gressivememory impairment andmagnetic resonance imaging demon-
strated a 3 cm irregularly enhancing tumour of the third ventricle,
involving bilateral thalami and superior midbrain with obstructive hy-
drocephalus and leptomeningeal enhancement. The tumourwasmostly
resected but the patient died 1month later. Pathologic workupwas per-
formed on the surgically resected brain tumour tissue; H$_amp_$amp;E
and immunohistochemistry for GFAP, p53, Ki67 and mIDH1 (R132H).
Nuclear expressions of MLH1, MSH2, MSH6 and PMS2 within theCC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Immunohistochemical antibody Manufacturer and dilution
GFAP Cellmark, prediluted
p53 Ventana, prediluted
Ki67 Ventana, prediluted
mIDH1 (R132H) Histobio Tec, 1/50
MLH1 Biocare, 1/25
MSH2 Calbiochem 1/1000
MSH6 BD, 1/400
PMS2 BD, 1/100
Fig. 1. Low grade astrocytoma a — Low power H$_amp_$amp;E showing the tumour to h
intraparenchymal component showing an inﬁltrative low grade astrocytomawith oval nuclei an
and cellular with roundermore eccentric nuclei and scatteredmultinucleated giant cells; the tu
loss of nuclear MSH2 staining compared to the normally stained endothelia and lymphocytes
46 A. Alkhotani et al. / Human Pathology: Case Reports 6 (2016) 45–47tumour were compared to the endothelial and ependymal cells within
the brain. Immunohistochemical antibodies used are listed in Table 1.
No post mortem examination was done.3. Results
H$_amp_$amp;E stained sections showed a low grade astrocytoma
with intraparenchymal, leptomeningeal and intraventricular compo-
nents (Fig. 1a). The intraparenchymal component was an inﬁltrative
low grade astrocytoma with oval nuclei and a densely ﬁbrillaryave intraparenchymal and intraventricular components; b — H$_amp_$amp;E of the
d a densely ﬁbrillary background; c— the intraventricular component ismore discohesive
mour cells are strongly positive for GFAP (d), p53 (e), andmIDH1 (R132H) (f), and there is
(red arrow on (e)).
47A. Alkhotani et al. / Human Pathology: Case Reports 6 (2016) 45–47background (Fig. 1b) and eosinophilic granular bodies and calciﬁcations
were seen focally. The intraventricular and leptomeningeal components
were discohesive and myxoid with more pleomorphic eccentric nuclei
and scattered multinucleated cells (Fig. 1c). Mitoses, necrosis and mi-
crovascular proliferation were not seen. On immunohistochemical
staining most tumour cells were strongly immunopositive for GFAP
which highlighted examples of coarse cytoplasmic processes and bipo-
lar lesional cells (Fig. 1d), and they were strongly positive for p53 (Fig.
1e) and mIDH1 (R132H) (Fig. 1f). Nuclear ATRX expression was lost.
The Ki67 proliferative index was less than 1% throughout. The tumour
cells showed retention of nuclear MLH1 and PMS2 staining and com-
plete loss of MSH2 and MSH6 compared to the normally stained
ependyma and endothelia (Fig. 1g).
4. Discussion
There are two unique aspects to our case.First, low grade astrocyto-
ma histology has only rarely been previously reported in LS families
[6,7].Second, to our knowledge, this is the ﬁrst case of IDH1mutated gli-
oma reported in the setting of an LS family [8,9].Whether the presence
of a mutated IDH1 glioma in a patient with MSH2 mutation is a chance
occurrence or is informative about oncogenesis remains uncertain.
5. Conclusion
Brain tumours reported in Lynch syndrome families have predomi-
nantly been glioblastoma or medulloblastoma, and the present case ex-pands this spectrum to include mIDH1 (R132H) mutated low grade
astrocytoma.
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